CDK4 and cancer: Sunitinib was identified as one of the most promising drugs in both A375 and SK-MEL-28 cells, in addition to CDK4/6 inhibitors, which have been reported to synergize with BET inhibitors in cancer cells, thus supporting the validity of our screen (Fig. 1b, c).